Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Lynx1 Capital Management LP

Q4 2025 · 13F-HR

Lynx1 Capital Management LPholdings as filed

Filed 2026-02-17 · accession 0001910456-26-000001

$494.0M
Reported value
22
Positions
2025-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
86150R107STOKSTOKE THERAPEUTICS INC$171.5M34.7%5,404,674CommonSHARED
G3855L106GHRSGH RESEARCH PLC$132.2M26.8%10,406,575CommonSHARED
230031106CGEMCULLINAN THERAPEUTICS INC$92.8M18.8%8,963,500CommonSHARED
24823R105DNLIDENALI THERAPEUTICS INC$28.7M5.81%1,738,750CommonSHARED
12529R107CCCCC4 THERAPEUTICS INC$13.6M2.74%7,098,133CommonSHARED
98401F105XNCRXENCOR INC$10.8M2.19%705,558CommonSHARED
N44445109IMTXIMMATICS N.V$9.7M1.96%921,950CommonSHARED
89854M101TCRXTSCAN THERAPEUTICS INC$8.0M1.62%8,019,148CommonSHARED
702712209PASGPASSAGE BIO INC$7.4M1.49%623,704CommonSHARED
500946108KRROKORRO BIO INC$5.4M1.10%677,915CommonSHARED
74019P207DTILPRECISION BIOSCIENCES INC$4.1M0.84%993,913CommonSHARED
64136E102NEUPNEUPHORIA THERAPEUTICS INC$3.4M0.69%875,228CommonSHARED
00847X104AGIOAGIOS PHARMACEUTICALS INC$2.2M0.44%79,624CommonSHARED
156944100CGONCG ONCOLOGY INC$1.3M0.27%31,591CommonSHARED
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$799,5350.16%12,043CommonSHARED
25056L103DSGNDESIGN THERAPEUTICS INC$652,0600.13%69,516CommonSHARED
29384C108TRDAENTRADA THERAPEUTICS INC$531,3630.11%51,689CommonSHARED
95075A107HOWLWEREWOLF THERAPEUTICS INC$415,5290.08%655,926CommonSHARED
56565P103MPLTMAPLIGHT THERAPEUTICS INC$236,7240.05%13,477CommonSHARED
37148K209GENERATION BIO CO$142,0000.03%25,000CommonSHARED
N71542109PRQRPROQR THRAPEUTICS N V$138,3420.03%68,486CommonSHARED
03828A101APLTAPPLIED THERAPEUTICS INC$41,0500.01%410,500CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.